The results of our study are consistent with a previous finding from a French group combining two breast cancer trials randomizing to anthracycline-based vs. no chemotherapy, which found that even though TIL counts on primary tumor specimens are prognostic (particularly in triple-negative and HER2-positive breast cancer), they do not predict benefit from anthracycline chemotherapy [42]. The gene discussed is ERBB2; the disease is neoplasm.